|
|
|
|
|
|
|
HIGHLIGHTS FROM THE 2024 AMERICAN UROLOGICAL ASSOCIATION ANNUAL MEETING |
|
|
|
|
|
|
| Paradigm-Shifting, Practice-Changing Clinical Trials in Urology: TAR-200 in Patients with BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results from the SunRISe-1 Study |
| Joseph Jacob, MD, MCR |
| Joseph Jacob discussed results from the SunRISe-1 study assessing TAR-200 in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer. The standard of care for BCG-unresponsive high-risk non-muscle invasive bladder cancer is radical cystectomy, however, this is a life-changing operation associated with considerable morbidity and impact on quality of life and a 90-day mortality risk of up to 8%. Moreover, many patients are unwilling to undergo radical cystectomy. |
|
|
|
|
|
| Paradigm-Shifting Clinical Trials in Urology: SWOG S1011 - Subgroup Analysis of the Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Lymphadenectomy Performed at Time of Radical Cystectomy for MIBC |
| Seth Lerner, MD, FACS |
| Seth Lerner discussed subgroup analysis results from SWOG S1011, assessing standard versus an extended lymphadenectomy at the time of radical cystectomy for muscle-invasive bladder cancer (MIBC). Patients undergoing radical cystectomy and extended lymph node dissection had increased node yield, but similar pathologic T stage and rate of node metastasis. |
|
|
|
|
|
|
Bladder Cancer: Non-Invasive I
|
|
| N-803 plus BCG Complete Response Rate in Non-Muscle Invasive Bladder Cancer CIS Subjects: BCG Refractory, Relapsed, Checkpoint Failure, and Chemotherapy Failure; Updated Results (QUILT 3.032) |
| Patrick Soon-Shiong, MD |
| The 2024 AUA Annual Meeting was host to a non-invasive bladder cancer moderated poster session. Dr. Patrick Soon-Shiong presented updated results of the QUILT 3.032 trial of N-803 plus BCG in patients with BCG-unresponsive high-grade NMIBC. Dr. Patrick Soon-Shiong presented the interim results of the open-label, three-cohort, multicenter phase 2/3 study QUILT 303, reporting on the duration of response and the complete response rate for 94 subjects with BCG-unresponsive CIS. |
|
|
|
|
|
|
|
|
|
|
| Beyond the Tumor: Exploring the Financial Toxicity of Non-Muscle Invasive Bladder Cancer in a Diverse, Urban Population |
| Julia Nadelmann |
| Julia Nadelmann presented a study of the financial toxicity of non-muscle invasive bladder cancer (NMIBC) in a diverse urban population. Financial toxicity assesses the negative impact of treatment costs on patients’ lives and has been used across several diseases and cancer types. Patients endorsing financial toxicity are more likely to experience delays in care, medication rationing, and lower quality of life. |
|
|
|
|
|
| Urinary Minimal Residual Disease Detection Predicts Recurrence in BCG-Unresponsive NMIBC and Quantifies Molecular Response to Nadofaragene Firadenovec |
| Vikram Narayan, MD |
Vikram Narayan presented an analysis of urinary minimal residual disease detection for predicting recurrent in BCG unresponsive non-muscle invasive bladder cancer and quantifying molecular response to nadofaragene firadenovec. This was an open-label, multicenter, parallel-arm, phase II study of 43 patients with BCG-unresponsive NMIBC who received intravesical nadofaragene.
|
|
|
|
|
|
| A Phase II Trial of Intravesical Gemcitabine and Docetaxel (GEMDOCE) in the Treatment of BCG-Naïve Non-Muscle Invasive Urothelial Carcinoma of the Bladder |
| Andrew Gabrielson, MD |
| Andrew Gabrielson presented findings from a phase II trial investigating intravesical gemcitabine and docetaxel for high-risk, BCG-naïve non-muscle invasive bladder cancer (NMIBC). The study showed a 100% complete response rate at 3 months and a 92% recurrence-free survival at 12 months, with manageable adverse events. These promising results support further investigation through the EA8212 (BRIDGE) phase 3 trial comparing gemcitabine plus docetaxel to standard BCG therapy in high-risk NMIBC patients. |
|
|
|
|
|
| Phase I Study of Intravesical Fc-Optimized Anti-CD40 Agonist Antibody 2141-V11 for Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) |
| Bernard Bochner, MD, FACS |
| Bernard Bochner presented findings from a phase I study of intravesical Fc-optimized anti-CD40 agonist antibody 2141-V11 for non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG) at the 2024 AUA Annual Meeting. The study demonstrated that intravesical 2141-V11 was well-tolerated with no dose-limiting toxicities observed up to 70 mg, with the maximal tolerated dose (MTD) not reached. |
|
|
|
|
|
| Combination Regimen of Intravesical Docetaxel, Gemcitabine, and Cisplatin in Patients with BCG-unresponsive Non-Muscle Invasive Urothelial Carcinoma of the Bladder |
| Benjamin Joffe, MD |
| Benjamin Joffe presented findings on the combination of intravesical docetaxel, gemcitabine, and cisplatin in patients with BCG-unresponsive non-muscle invasive bladder cancer. This retrospective study showed that nearly 45% of patients achieved a complete response following induction therapy, with approximately two-thirds avoiding radical cystectomy over the study period. |
|
|
|
|
|
| Comparison of BCG to Gemcitabine/Docetaxel in The Intermediate Risk Group Composed Mostly of TaHG |
| Reuben Ben David, MD |
| Reuben Ben David presented findings comparing BCG to gemcitabine plus docetaxel in intermediate-risk NMIBC, predominantly high-grade Ta disease. The retrospective analysis of 118 patients showed that gemcitabine/docetaxel was associated with worse any-grade recurrence-free survival compared to BCG, although high-grade recurrence-free survival rates were similar. These results highlight the need for tailored treatment approaches for high-grade Ta patients, suggesting that prospective trials with larger cohorts are necessary to validate these findings. |
|
|
|
|
|
|
|
|
|
|
